Search details
1.
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Cancer Immunol Immunother
; 70(6): 1583-1592, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33231726
2.
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
Clin Genitourin Cancer
; 20(5): 498.e1-498.e9, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35768316
3.
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Clin Lung Cancer
; 22(4): 351-360, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33558194
4.
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Cancers (Basel)
; 12(5)2020 May 08.
Article
in English
| MEDLINE | ID: mdl-32397295
5.
Biomarkers of response to advanced prostate cancer therapy.
Expert Rev Mol Diagn
; 20(2): 195-205, 2020 02.
Article
in English
| MEDLINE | ID: mdl-31986925
Results
1 -
5
de 5
1
Next >
>>